Krishnamurthy Hari, Suresh Chithra, Siriwardhane Thushani, Krishna Karthik, Song Qi, Jayaraman Vasanth, Wang Tianhao, Bei Kang, Rajasekaran John J
Vibrant Sciences LLC, Santa Clara, California, USA
Biological, Vibrant America, San Carlos, California, USA.
BMJ Open. 2025 Jan 6;15(1):e076397. doi: 10.1136/bmjopen-2023-076397.
To evaluate the association between thyroid disease and diabetes markers.
Retrospective cohort study.
The study was conducted in a diagnostic setting where the primary care providers recommended the patients to test for thyroid and diabetes panels.
The thyroid and diabetes markers were tested in 32 787 subjects with suspected thyroid and related conditions who visited Vibrant America Clinical Laboratory between January 2015 and June 2019.
Our general prevalence results showed that homeostatic model assessment-insulin resistance (HOMA-IR) was elevated in overt hypothyroid subjects (43.7%) and overt hyperthyroid subjects (42.2%). Glycated hemoglobin (HbA1C) was elevated in subclinical hypothyroid subjects (19.2%), overt hypothyroid subjects (22.3%) and overt hyperthyroid subjects (21.2%). Glucose was significantly elevated in subclinical hypothyroid subjects (24.2%) and overt hyperthyroid subjects (31.0%). Insulin was significantly elevated in overt hypothyroid subjects (15.1%). Interestingly, we found that 70.3% of subjects who had their HOMA-IR score escalated from negative (HOMA-IR<2.7) to positive (HOMA-IR>2.7) during their multiple visits had anti-thyroid peroxidase (anti-TPO) 369 (±242) days prior to the onset of this change.
Our findings showed that anti-TPO levels are elevated before the onset of insulin resistance, indicating its potential use as a predictive marker.
评估甲状腺疾病与糖尿病标志物之间的关联。
回顾性队列研究。
该研究在一个诊断环境中进行,初级保健提供者建议患者进行甲状腺和糖尿病相关检测。
2015年1月至2019年6月期间,在活力美国临床实验室就诊的32787名疑似甲状腺及相关疾病的受试者接受了甲状腺和糖尿病标志物检测。
我们的总体患病率结果显示,显性甲状腺功能减退受试者(43.7%)和显性甲状腺功能亢进受试者(42.2%)的稳态模型评估胰岛素抵抗(HOMA-IR)升高。糖化血红蛋白(HbA1C)在亚临床甲状腺功能减退受试者(19.2%)、显性甲状腺功能减退受试者(22.3%)和显性甲状腺功能亢进受试者(21.2%)中升高。亚临床甲状腺功能减退受试者(24.2%)和显性甲状腺功能亢进受试者(31.0%)的血糖显著升高。显性甲状腺功能减退受试者的胰岛素显著升高(15.1%)。有趣的是,我们发现,在多次就诊期间,HOMA-IR评分从阴性(HOMA-IR<2.7)升至阳性(HOMA-IR>2.7)的受试者中,70.3%在这种变化发生前369(±242)天有抗甲状腺过氧化物酶(抗-TPO)。
我们的研究结果表明,抗-TPO水平在胰岛素抵抗发生前升高,表明其作为预测标志物的潜在用途。